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Abstract Ulcerated diabetic foot is a complex problem. Ischaemia, neuropathy and
infection are the three pathological components that lead to diabetic foot complications,
and they frequently occur together as an aetiologic triad. Neuropathy and ischaemia are
the initiating factors, most often together as neuroischaemia, whereas infection is mostly
a consequence. The role of peripheral arterial disease in diabetic foot has long been
underestimated as typical ischaemic symptoms are less frequent in diabetics with ischaemia
than in non-diabetics. Furthermore, the healing of a neuroischaemic ulcer is hampered
by microvascular dysfunction. Therefore, the threshold for revascularising neuroischaemic
ulcers should be lower than that for purely ischaemic ulcers. Previous guidelines have
largely ignored these speciﬁc demands related to ulcerated neuroischaemic diabetic feet.
Any diabetic foot ulcer should always be considered to have vascular impairment unless
otherwise proven. Early referral, non-invasive vascular testing, imaging and intervention
are crucial to improve diabetic foot ulcer healing and to prevent amputation. Timing is
essential, as the window of opportunity to heal the ulcer and save the leg is easily missed.
This chapter underlines the paucity of data on the best way to diagnose and treat these
diabetic patients. Most of the studies dealing with neuroischaemic diabetic feet are not
comparable in terms of patient populations, interventions or outcome. Therefore, there
is an urgent need for a paradigm shift in diabetic foot care; that is, a new approach
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and classiﬁcation of diabetics with vascular impairment in regard to clinical practice and
research. Amultidisciplinary approach needs to implemented systematically with a vascular
surgeon as an integrated member. New strategies must be developed and implemented
for diabetic foot patients with vascular impairment, to improve healing, to speed up
healing rate and to avoid amputation, irrespective of the intervention technology chosen.
Focused studies on the value of predictive tests, new treatment modalities as well as
selective and targeted strategies are needed. As speciﬁc data on ulcerated neuroischaemic
diabetic feet are scarce, recommendations are often of low grade.
© 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Diabetic foot ulcers are a major healthcare problem.
In 2011, 350 million people worldwide (6.6% of the
population) and more than 55 million in Europe suffer from
diabetes mellitus,1 and estimates for 2025 cite a total
of over 65 million patients.1 Complications of foot ulcers
are the leading cause of hospitalisation and amputation
in diabetic patients. Indeed, 20––40% of the healthcare
resources spent on diabetes are related to diabetic feet.2,3
Individuals suffering from diabetes and neuropathy with
no other confounders will develop an ulcer in 7––10% of the
cases annually, whereas the rate for patients with additional
risk factors –– such as peripheral arterial disease (PAD),
foot deformity, previous ulcers or previous amputation –– is
25––30%.2––4
Major amputation will be needed within 1 year in 5––8%
of patients with diabetic ulcers.5––7 Of all amputations
on diabetic patients, 85% are preceded by a foot ulcer
which subsequently deteriorates to a severe infection or
gangrene.2––4 Diabetes increases the risk of amputation
8-fold in patients aged >45 years,8 12-fold in patients aged
>65 years and 23-fold in those aged 65––74 years.9
2. Neuropathy
Ischaemia, neuropathy and infection are the three patho-
logical components that lead to diabetic foot complications,
and they frequently occur together as an aetiologic triad.10
Neuropathy and ischaemia are the initiating factors, with a
different weight in different patients (Fig. 1), and infection
is mostly a consequence.11
Fig. 1. Pathway to diabetic ulcer. Modiﬁed from the International Working Group on the Diabetic Foot, International Consensus on the
Diabetic Foot, 1999, with permission.
S62 M. Lepa¨ntalo et al.
Due to the lack of protective sensation, the foot
is vulnerable to unattended minor injuries caused by
excess pressure, mechanical or thermal injury. Motor
neuropathy alters the biomechanics and, gradually, the
foot anatomy. Foot deformities, limited joint mobility and
altered loading of the foot are obvious consequences from
these disarrangements. The most important feature of the
treatment of any ulcer with neuropathy is to restrict weight
bearing, irrespective of the presence of ischaemia.
The treatment of purely neuropathic ulcers is beyond
the scope of these guidelines, and neuropathy is further
dealt with only in conjunction to ischaemia –– i.e. as
neuroischaemic ulcers. For the purposes of this chapter, the
term diabetic foot refers to an ulcerated diabetic foot with
vascular impairment.
3. Ischaemia and neuroischaemia of the
diabetic foot
3.1. Underestimation of the role of ischaemia
Poor glucose control accelerates the manifestation of PAD.
For every 1% increase in haemoglobin A1c (HbA1c), there
is a corresponding increase of 25––28% in the relative risk
of PAD.12 Diabetes increases the prevalence of symptomatic
PAD 3.5-fold in men and 8.6-fold in women.13 Recent large
European cohort studies of individuals with diabetes and
foot ulcers conﬁrm that at least half are of neuroischaemic
or ischaemic origin.14––16 Yet the strategy of prevention
and treatment of the diabetic foot has predominantly
been focused on neuropathy and its consequences,2,17
although ischaemia is the most important factor preventing
healing.11 PAD in diabetics is often multisegmental, typically
infrapopliteal and poorly collateralised.18––20 Ischaemia has
been reported to be at least a contributing factor in 90% in
diabetics undergoing major amputation.21
Recommendation
Ischaemia should not be excluded as a cause of a diabetic
foot ulcer unless proven absent.22,23 (Level 5; Grade D)
3.2. Inadequate understanding of neuroischaemia
Neuroischaemia is the combined effect of diabetic neuro-
pathy and ischaemia, impairing the oxygen delivery to meet
metabolic tissue demands in a synergetic way. Macrovascular
disease and microvascular dysfunction both impair perfusion
in a diabetic foot.24 Peripheral autonomic neuropathy, or
auto-sympathectomy, causes deﬁcient sweating and altered
blood ﬂow regulation with an opening of arteriovenous
shunts and precapillary sphincter malfunction, which
decreases nutritive blood ﬂow and manifests as warm, dry
skin, increasing the likelihood of skin breakdown.25
The microvascular dysfunction is further characterised by
the subsequent capillary leakage and venous pooling as well
as hormonal activity in the vessel and inﬂammation in the
wall, all indicating that decreased perfusion in the diabetic
foot is more complex and not only related to PAD.26––28 Yet
PAD is the most important cause of vascular impairment of
diabetic foot.24
Recommendation
In neuroischaemic legs, healing is primarily affected by
the severity of ischaemia.11 Therefore, from a practical
point of view, neuroischaemic and ischaemic lesions
should be considered together as both may require
revascularisation. (Level 2b; Grade C)
3.3. Assessment of vascular impairment beyond ischaemia
The use of rigid non-invasive methods is mostly based on
the haemodynamic changes in the macrovascular arterial
tree, and criteria applicable to non-diabetic legs are not
good enough to predict the healing of diabetic foot lesions.23
There is a clear need to recognise decreased perfusion
or vascular impairment as an indicator for the need for
revascularisation in the diabetic foot in order to achieve
and maintain healing and to avoid or delay a future
amputation.4,6,16,23,29––31
Recommendation
The International Working Group for the Diabetic Foot
recommends further vascular studies in case the ulcer
has not healed with proper treatment in 6 weeks even
if initial diagnostics have suggested only questionable or
mild disease.22 (Level 5; Grade D)
Critical issue
Criteria for impaired perfusion should be established.
3.4. Delay in revascularisation
As less than 25% of diabetics with PAD report intermittent
claudication, and rest pain is far less common than in non-
diabetics, the diagnosis of ischaemia is often delayed.2 The
obvious consequence has been that a vascular consultation
is arranged too late for diabetics. Indeed, 30––50% of their
foot ulcers are already gangrenous, and, therefore, vascular
surgeons are too often not consulted at all.2,4
Recommendation
To prevent a delay in vascular consultation and revascular-
isation, early non-invasive vascular evaluation is important
in identifying patients with poor ulcer healing and a high
risk for amputation.2,4,6,17,29––31 (Level 2b; Grade B)
3.5. Ischaemia, infection and tissue damage
Neuroischaemic ulcers are susceptible to infection. Infection
is seldom the direct cause of an ulcer but strongly related
to the probability of amputation, especially in combination
with ischaemia (PAD).11 Deep infections are manifested
either as osteomyelitis or a soft tissue infection spreading
along the tendons in the compromised foot. A deep infection
is a limb-threatening condition and the immediate cause
of amputation in 25––50% of diabetic patients.2,4,32––34 In
several studies, the outcome of deep foot infection has been
related to the extent of tissue involved, comorbidity and
co-existing PAD.2,4,14,16
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Recommendation
The combination of ischaemia and infection always
necessitates urgent treatment, as “time is tissue”.22
(Level 2c; Grade C)
4. Clinical examination from the vascular
perspective
4.1. History
4.1.1. General
The primary evaluation with regard to the diabetic foot
should include information on the presence of concomitant
diseases and their medications; cardiovascular risk factors;
occupation and hobbies; lifestyle; smoking as well as the
use of alcohol, drugs and other intoxicants; in addition
to diabetes-related complications, especially nephropathy,
retinopathy and neuropathy. Special attention should also
be paid to impaired vision, renal replacement therapy,
previous foot education, social isolation and poor access to
healthcare.2
4.1.2. Foot-speciﬁc history
The main aim of the examination of a diabetic foot is to
assess the risk factors for foot ulceration and, in case there
already is an ulcer, to evaluate its speciﬁc aetiology and
duration to allow targeted treatment.17,25
4.2. Inspection
A clinical examination of the foot of a diabetic patient
should be performed at least once a year and more
frequently in the presence of risk factors. The role of a
regular inspection of the diabetic foot cannot be emphasised
enough.3,11,35 As Andrew Boulton has put it, “For one mistake
made for not knowing, ten mistakes are made for not
looking.” A neuropathic foot frequently has a characteristic
appearance upon inspection.10
4.3. Vascular clinical examination
Pulse palpation is the cornerstone of vascular examination
although it is not necessarily a method of good reproducibil-
ity.36 Therefore, clinically signiﬁcant arterial disease can
most often be ruled out only if both dorsalis pedis and
posterior tibial pulses are palpable with certainty. Yet, in
diabetics even this may not sufﬁce to exclude impaired
perfusion.37 Furthermore, the arteria dorsalis pedis pulse is
missing in 8% and tibialis posterior pulse in 3% of healthy
individuals.38
An ischaemic foot may appear pink and relatively warm
even with impaired perfusion due to arteriovenous shunting.
Delayed discolouration (rubor) or venous reﬁlling >5 s on
dependency may indicate poor arterial perfusion.39 Slow
capillary reﬁlling time has little diagnostic value.39
Recommendation
Every foot ulcer should be examined for the presence of
ischaemia.2 (Level 5; Grade 4)
4.4. Neurological clinical examination
Sensory loss tested by pressure perception with a 10-
gram (5.07) Semmes––Weinstein monoﬁlament is the most
important single test.2,17 Vibration perception using a
128Hz-tuning fork, pinprick discrimination and tactile
sensation testing with cotton wool on the dorsum of the
foot, as well as testing Achilles tendon reﬂexes, belong to
the neurological examination in addition to looking for foot
deformities or bony prominences.2
Recommendation
Every foot ulcer should be examined for the presence of
neuropathy.2 (Level 5; Grade 4)
4.5. Ulcers
The diabetic foot ulcer is not a disease of the skin
but a sign of abnormal loading and impaired perfusion.
A systematic classiﬁcation of foot ulcers would be helpful for
the comparison of data, but only few scoring systems have
been validated.40 The most frequently used systems include
perfusion, the extent and size of tissue involvement as well
as infection.29,41
Critical issue
The validity of scoring systems needs to be evaluated
speciﬁcally in ischaemic diabetic ulcers.
4.6. Infection
Ulcer infections are diagnosed clinically on the basis of local
signs and symptoms of inﬂammation. These include purulent
secretion in the ulcer or at least two of the following
signs or symptoms: redness, warmth, swelling, pain, delayed
improvement or bad odour. The clinical signs of infection can
be reduced due to diminished leucocyte function, PAD, poor
metabolic control and neuropathy.42 Occasional systemic
signs are fever and poor general condition.34,43 In almost
50% of patients with diabetes and deep foot infections,
signs such as increased white blood cell count, erythrocyte
sedimentation rate, C-reactive protein concentration and
fever have been found absent, resulting in a delay in
diagnosis.32––34 Some patients with a diabetic foot infection
also have a worsening in their glycaemic control. A swollen
foot with a long-lasting ulceration or a red swollen digit
should always arouse suspicion of an infection extending
to deep tissue. The most common sign of a diabetic
foot infection with an ulcer is increased exudation rate.32,44
Unrooﬁng a superﬁcial eschar may reveal deeper abscesses.10
Indeed, the severity of infection should be assessed after
debridement, based on its extent and depth as well as the
presence of any systemic ﬁndings.22 Tissue specimens should
be obtained by biopsy, curettage or aspiration, preferable to
wound swab specimens, prior to starting empirical antibiotic
therapy.45––47
A continuous extension of a soft tissue infection to the
underlying bone poses both diagnostic and therapeutic chal-
lenges.32––34,48 Imaging studies may help detect pathological
ﬁndings in the bone.49 Plain radiographs of the foot may be
of value in revealing the presence of a foreign body, gas,
osteolysis or joint effusion. Radiological diagnosis is often
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difﬁcult because changes suggesting osteomyelitis usually
take several weeks to become visible on X-ray.
Fever as well as an increased erythrocyte sedimentation
rate (ESR), white cell count and C-reactive protein
concentrations (CRP) are usually helpful in recognising soft
tissue infections or abscess. An MRI, bone scan or CT scan
can be of value in evaluating the presence and extent of a
deep foot infection.
Recommendation
Every diabetic foot ulcer should be examined for the
presence of infection.2 (Level 5; Grade D)
4.7. Non-invasive vascular studies –– special considerations
related to the diabetic foot
In the case of any uncertainty as to foot perfusion, the
measurement of ankle pressure, the ankle-brachial systolic
pressure index (ABI) and toe pressures should be included.
Normal ABI values range between 0.9 and 1.3, as high values
suggest non-compressible arteries (pseudohypertension)
characteristic of advanced mediasclerosis, which is typical in
diabetes. Less severe calciﬁcation may result in a normal ABI
despite clinically signiﬁcant PAD.50 In a series of 554
diabetics with vascular impairment, ankle pressures could
not be measured in 35% of the patients.51 An ABI <0.4––0.45,
absolute systolic ankle pressure <55mmHg and toe pressure
<30mmHg have most frequently been used to indicate the
need for revascularisation.10,52,53 Pseudohypertension may
be revealed by pulse volume recording (PVR),54 but there are
not enough data to support the use of methods such as the
pole test.55 In hand-held Doppler examination, an absent or
monophasic ﬂow velocity signal from a foot artery indicates
occlusion or collateral ﬂow.
Recommendation
Trust ABI when low but not when high. An ABI <0.6
indicates signiﬁcant ischaemia in respect to wound healing
potential, whereas an ABI >0.6 has little predictive value
and, therefore, at least the toe pressure should be
measured.22 (Level 5; Grade D)
Toe pressure may give more reliable information on
the level of distal ﬂow capacity but, as reported in one
study, it could not be measured in 16% of cases due to a
previous amputation or gangrene of the big toe.51 Vascular
intervention has been suggested feasible for diabetics
with an ulcer as well as ankle pressures <80mmHg54 and
toe pressure <55mmHg.56 The probability of ulcer healing
is clearly related to available perfusion pressures and,
regardless of the method used, follows a sigmoid curve
(Fig. 2).17
Recommendation
An ulceration of the foot in diabetes will generally heal if
the toe pressure is >55mmHg, whereas healing is usually
severely impaired when toe pressure is <30mmHg.22
(Level 2b; Grade B)
Transcutaneous oxygen pressure (TcPO2) <30mmHg has
been considered to predict that the infection will not
Fig. 2. Probability of ulcer healing as related to different
levels of systolic ankle pressure, toe pressure and TcPO2. From
the International Consensus on the Diabetic Foot, 1999, with
permission.
resolve itself and the ulcer will not heal.52 The accuracy of
these measurements in patients with critical leg ischaemia
has been questioned, especially in the presence of tissue
oedema.53,57Nevertheless, TcPO2 may be a useful method of
identifying tissue lesions that may heal with conservative
treatment.58,59 TcPO2-values >40mmHg support conservative
treatment alone as the ﬁrst approach as >90% of the ulcers
healed.59,60
Recommendation
Ulceration of the foot in diabetes will generally heal if the
TcPO2 is >50mmHg. Healing is usually severely impaired
when TcPO2 is <30mmHg.22 (Level 2b; Grade B)
Low ABI, ankle pressure, toe pressure and TcPO2 suggest
that a diabetic ulcer may not heal, but the limitations of
each technique should always be considered.
4.8. Vascular imaging –– special considerations related to
the diabetic foot
Extensive calciﬁcation of the infrapopliteal arterial tree
may prevent proper duplex diagnostics as well as computed
tomography angiography, although the use of multisliced
devices decreases interpretation difﬁculties caused by
arterial wall calciﬁcations.61––64 MRA may have limited
spatial resolution and the images may be distorted by
previous stents, implants and ﬂow disturbances. The use
of the paramagnetic contrast material gadolinium has been
reported to cause nephrogenic systemic ﬁbrosis typically in
patients with renal failure.65––67
Recommendation
Any of the techniques are useful for mere imaging as
the accuracies of the different techniques in diagnosing
stenosis of >50% in the infrapopliteal segment are
acceptable and similar when using DSA as the reference.61
(Level 2b; Grade B)
A systematic angiographic classiﬁcation of infrapopliteal
occlusive lesions would be valuable in order to have
comparable data for future comparisons of different
revascularisation techniques. At present, at least three
classiﬁcations are in use,19,23,68 each with different degrees
of validation and inter-observer agreement.19,69––71 None
of them has gained larger acceptance in the practice of
assessing angiographic patterns of ulcerated diabetic feet.
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Chronic renal failure is increasingly common in diabetics
with a foot ulcer. Metformin treatment should be discon-
tinued before angiography as it may cause lactic acidosis.72
Renal insufﬁciency inﬂuences the choice of imaging method,
because contrast media are nephrotoxic agents. In the case
of mild chronic renal failure, regular DSA and CTA can
be performed, but intravenous hydration of the patient is
recommended before and after the examination.72,73 In more
severe cases, selective angiography with a minimal amount
of contrast media, preferably diluted non-ionic iso-osmolar,
can produce excellent imaging when focused on the target
lesion.73 Alternatively, duplex ultrasound can be used for
imaging and sometimes also for guiding the endovascular
procedure.74
Recommendation
Detailed visualisation of infrapopliteal arteries, including
the arteries of the foot, is necessary for a complete
evaluation of diabetic patients.22 (Level 5; Grade D)
Critical issue
The risks of gadolinium-enhanced MRA for imaging diabetic
patients with kidney failure should be considered and further
evaluated.
5. Treatment of ulcerated neuroischaemic
diabetic feet
5.1. Multifactorial approach mandatory
The complexity of diabetic foot ulcers necessitates in-
depth knowledge of the underlying pathophysiology and a
multifactorial approach in which aggressive management of
ischaemia and infection is of major importance (Table 1).
Recommendation
Patients in need of revascularisation to improve per-
fusion and achieve healing should be identiﬁed by an
extensive clinical examination and non-invasive, vascular
testing.22,23 (Level 5; Grade D)
Metabolic control also plays an important role in
comprehensive treatment. Blood glucose control may be
difﬁcult because of infection. If the patient is on oral
antidiabetic drugs, a temporary switch to insulin may be
necessary. On the other hand, high blood glucose worsens
infection and is associated with poorer operative results,
morbidity and mortality. The recommended target level of
HbA1c should be <7.0––7.5% but higher if hypoglycaemic
episodes are a problem, and the LDL level should be
<1.8mmol/L and blood pressure <130/80mmHg, while
less stringent goals should be accepted for elderly and
multimorbid patients.75
Recommendation
Intensive management of diabetes, including glycaemic
and platelet aggregation control, treatment of hyperten-
sion and dyslipidaemia as well as non-pharmacological
interventions, decreases vascular complications in the
long run.76 (Level 1a; Grade A)
5.2. Management of infection
Antibiotic therapy is necessary for virtually all infected
wounds, but it is not beneﬁcial for non-infected ulcers
and is insufﬁcient without appropriate wound care. In
long-standing ulcers or ulcers with delayed healing and
ischaemia or necrotic tissue, polymicrobial ﬂora with an
unknown causative agent is frequently present. Broad-
spectrum empirical therapy is not routinely required but is
indicated for moderate to severe infections.34,77 Antibiotic
therapy is continued until there is evidence that the
infection has been resolved but not necessarily until the
wound has healed.49
Patients with uncontrolled or limb-threatening infections
require immediate hospitalisation, immobilisation and
intravenous antibiotics. Infections accompanied by a deep
abscess, extensive bone or joint involvement, crepitus,
substantial necrosis or gangrene, or necrotising fasciitis,
need prompt surgical intervention. Infections can spread
extremely rapidly in a diabetic foot, which may lead to
a life-threatening general septic infection if treatment
is delayed. Urgent evaluation of lower limb circulation,
treatment of infections and surgical procedures, including
debridement and revascularisations, are often needed as
ﬁrst-line leg salvage strategies.48,50,78
Recommendation
Surgical intervention for moderate or severe infections
is likely to decrease the risk of major amputation.22
(Level 2c; Grade B)
5.3. Infrainguinal revascularisation
The crucial issue is to decide whether revascularisation
is needed for a certain lesion in a certain patient.10
Although non-invasive evaluation is helpful, the decision to
intervene is made according to the symptoms and clinical
ﬁndings.10 Anatomical imaging should be considered only as
strategic.73
If both an endovascular and a bypass procedure
are possible with an equal outcome to be expected,
endovascular treatments should be preferred.79 Especially
patients with chronic neuroischaemic ulcers, borderline toe
pressures and short lesions are candidates for endovascular
treatment. However, continuous surveillance and a low
threshold for secondary imaging, percutaneous transluminal
angioplasty (PTA) or bypass are basic principles when treat-
ing diabetic ulcers with an endovascular procedure.80 Bypass
grafting is to be used for long occlusions. Patency rates after
crural and pedal bypasses are similar in diabetics and non-
diabetics.81 (For femoropopliteal reconstructions, see Chap-
ter IV, Treatment of Critical Limb Ischaemia, pp. S43––S59.)
5.4. Infrapopliteal endovascular procedures
Endovascular therapy for infrapopliteal arterial disease is
gaining acceptance as a ﬁrst-line revascularisation method
to improve ulcer healing and limb salvage.79 The angioplasty
of isolated crural arterial lesions in diabetic patients with
an unhealed ulcer is also considered an effective and
safe therapeutic modality to avoid limb loss.82 There are
several studies showing good results and patency rates after
endovascular treatment of PAD with critical ischaemia.82––86
An important task for any revascularisation is to achieve
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Table 1 Multifactorial treatment of a diabetic foot ulcer
Goal Treatment
Improvement of perfusion Endovascular revascularisation (PTA)
Reconstructive vascular surgery (bypass)
Vascular drugs
Reduction of oedema
Hyberbaric oxygen
Treatment of infection Antibiotics (oral or parenteral)
Incision, drainage
Resection
Reduction of oedema External compression therapy
Intermittent compression (pumps)
Diuretics
Pain control Analgesic drugs (local or systemic)
Immobilisation, ofﬂoading, relief of anxiety and fear, TNS
Improvement of metabolic control Insulin treatment
Necessary nutritional support
Ofﬂoading Protective and therapeutic footwear
Insoles, orthosis
Total contact cast, walkers
Crutches, wheelchair, bed rest
Wound bed preparation Debridement, removal of debris
Topical treatment, dressings
Control of exudation, moist wound healing, GCSF infection control, NPWT
Tissue engineering, growth factors, matrix modulation
Removal of dead tissue Incision, drainage, amputation
Correction of foot deformities Corrective foot surgery, skin transplant, amputation
Improvement of general condition Fluid and nutrition replacement therapy
Aggressive treatment of concomitant disease, antiplatelet drugs, antihypertensive agents, lipid
decreasing agents
Cessation of smoking
Physiotherapy
Implementation of systematic care Patient and staff education
Support and follow-up
Multidisciplinary coordination, communication, staggered treatment chains
Improvement of concordance process oriented approach
GCSF, granulocyte colony-stimulating factor; NPWT, negative-pressure wound therapy; PTA, percutaneous transluminal angioplasty;
TNS, total neuropathy score.
at least one open infrapopliteal artery down to the foot,
preferably the artery that supplies the anatomical region
of the ulcer.80 The revascularisation of the plantar arch
and branches of the peroneal artery has been suggested
recently.87––89 The role of revascularisation of the speciﬁc
angiosome feeding the ulcer area has not been settled.90––93
5.5. Distal bypass procedures
If proximal vessels are free of major wall changes, inﬂow
to the graft can be taken from the superﬁcial femoral or
popliteal artery. Distal outﬂow vessels in diabetics are often
heavily calciﬁed, making the distal anastomosis challenging.
Clamping of vessels should be avoided to prevent any lesions
distal to the anastomosis. In such cases, gentle obstruction
balloons or tourniquet ischaemia provide better visibility
while the anastomosis is performed.94
The best graft material in distal bypasses is an autogenous
vein as it has better patency and resistance to infection
than a prosthetic graft. In a retrospective study, the Boston
Deaconess Hospital Group reported results from 1032 limb
salvage bypasses on the dorsalis pedis artery in 865 patients,
mostly diabetics.95 The patency of saphenous vein grafts was
better than all other conduits, with a secondary patency rate
of 67.6% vs. 46.3% at 5 years.95
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5.6. Immediate outcome after revascularisation
Several conditions, such as chronic renal failure requiring
long-term dialysis, an arterial graft of poor quality or
severe foot infection may indicate problems in leg salvage.96
Diabetes along with coronary artery disease, foot gangrene
and an urgent operation have been found to be independent
predictors of 30-day post-operative mortality and/or major
lower limb amputation after revascularisation for CLI.96
Systemic complications are encountered in approximately
10% of patients.97
5.7. Endovascular intervention or surgical bypass
There is not a single randomised controlled trial available
comparing endovascular and surgical revascularisation in
the treatment of impaired perfusion or critical ischaemia
in diabetics.97,98 A literature search revealed only seven
case series on revascularisations exclusively for diabetic
feet, provided that all patients were diabetics, had an ulcer
and were treated with an infrainguinal revascularisation
(Table 2).
As the infrapopliteal region is strongly affected by
diabetic PAD, current interest is increasingly targeted
on infrapopliteal revascularisations. New endovascular
techniques are rapidly evolving, despite the lack of RCTs
comparing open and endovascular revascularisations below
the knee. However, a recent meta-analysis is available for
both infrapopliteal surgery and infrapopliteal endovascular
interventions,106,107 with 29 and 30 studies included,
respectively. As 88% of the patients were diabetics and
88% had tissue loss in the bypass group with 2320 grafts
studied, the results may be accepted to be indicative of a
diabetic population. Unfortunately, only 61% of the patients
in the endovascular group were diabetics and only 76% of
them suffered from tissue loss, and the group therefore
rather represented a mixed group. No distal pressure data
were available. Primary and secondary mid-term patency
rates were better after bypass, but there was no difference
in limb salvage. The so-called patency/leg-salvage gap
seemed wider in the endovascular than in the surgical
series –– i.e. occlusion of the revascularised segment was
less likely to lead to amputation after an endovascular
procedure than surgical bypass. It is unclear whether
bypass patients had more severe ischaemia pre-operatively
or whether open surgery caused more leg morbidity. As
the BASIL trial showed, only 29% of patients are suitable
for both treatment methods, and patient populations are
thus bound to be different in endovascular and surgical
series.108 Bypass surgery and endovascular interventions are
therefore complementary techniques for revascularisation
in diabetic patients with non-healing ulcers.56 Indeed, an
analysis of infrapopliteal revascularisations in 611 diabetics
with 417 open and 194 endovascular revascularisations
showed a comparable outcome in terms of amputation-free
survival.79
Recommendation
The choice between different methods of revasculari-
sation –– open, endovascular or hybrid –– depends on
comorbidity, severity and extension of the arterial lesions
as well as the expertise of the centre. (Level 2c;
Grade B)
5.8. Microvascular ﬂaps
Microvascular free ﬂaps may be used to cover large tissue
defects and ulcers overtaking tendons and bones in diabetic
feet. In a recent review there were 17 case series, the
largest with 79 patients, 85% of whom were diabetics
and 66% of whom underwent a procedure combining
revascularisation and free ﬂap transfer.109 Revascularisations
of ischaemic diabetic feet combined with free ﬂap transfer
represent only a small fraction –– 4% at most –– of all
interventions to improve diabetic foot perfusion.110
Recommendation
When ischaemia coincides with a large diabetic foot
defect, major amputation may be prevented in an
ambulatory patient by combining revascularisation with
microvascular ﬂap transfer.109 (Level 4; Grade C)
5.9. Timing of the treatment of infection vs.
revascularisation
The most important step in controlling deep infection is
urgent incision and drainage of an abscess as well as
radical debridement of all infected, nonviable necrotic
tissue.32––34 The debridement should be done ﬁrst and
revascularisation thereafter.32––34,48 Distal bypass, when
needed, is usually delayed 2––5 days to control the
infection.94,111,112 Simultaneous revascularisation, preferably
endovascularly, in patients without systemic sepsis allows
maximising blood ﬂow at the initial debridement. Those
having a minor amputation before bypass have been
reported to fare worse than those who were revascularised
ﬁrst.113 Common sense is essential in this setting since
purulent lesions necessitate an amputation ﬁrst whereas
mummiﬁed gangrene allows revascularisation ﬁrst.
In situations with no limb-threatening infection, the
blood supply to the wound/extremity should be optimised
before surgical debridement to ensure that potentially
viable tissue is not unnecessarily removed. This may take
weeks.
Recommendation
The severity of infection guides the decision whether
to debride, to revascularise or to use a simultaneous
approach ﬁrst. (Level 2c; Grade C)
5.10. Debridement
Debridement after the damage control phase has been
studied extensively. A large review comprising surgical
debridement, surgical excision, the use of hyperbaric
oxygen, negative-pressure wound therapy, skin grafting,
bioactive local therapy products as well as electrical,
magnetic, ultrasound and laser therapies114 showed no
evidence to prove that one method was better than the
others with regard to the probability of healing according
to Cochrane Database.114––116
Recommendation
No single method is outstanding in terms of enhancing
diabetic ulcer healing. (Level 1c; Grade A)
S68 M. Lepa¨ntalo et al.
Ta
bl
e
2
Ca
se
se
ri
es
in
cl
ud
in
g
ex
cl
us
iv
el
y
in
fr
ai
ng
ui
na
l
re
va
sc
ul
ar
is
at
io
ns
fo
r
is
ch
ae
m
ic
ul
ce
ra
te
d
di
ab
et
ic
fe
et
Au
th
or
Pa
ti
en
ts
;
N
/g
en
de
r/
ag
e
(m
ea
n/
m
ed
ia
n)
Co
m
or
bi
di
ty
In
te
rv
en
ti
on
In
fr
a-
po
pl
it
ea
l
di
st
ri
bu
ti
on
30
-d
ay
co
m
pl
ic
at
io
ns
Fo
llo
w
-u
p
(f
u)
O
ut
co
m
e
Ro
se
nb
lu
m
,
19
94
99
39
/M
33
,
F6
/6
2.
3
yr
s
N
A
In
fr
ap
op
lit
ea
l
by
pa
ss
gr
af
ts
79
%
M
aj
or
am
pu
ta
ti
on
3%
,
m
or
ta
lit
y
N
A
21
.2
m
on
th
s
(m
ea
n)
,
ra
ng
e
2–
–6
4
83
%
pr
im
ar
y
ul
ce
r
he
al
in
g
w
it
h
gr
af
t
pa
te
nc
y
du
ri
ng
fu
W
o¨l
ﬂe
,
20
00
10
0
12
5/
N
A/
70
yr
s
CA
D
57
%,
ES
RD
25
%
In
fr
ap
op
lit
ea
l
by
pa
ss
gr
af
ts
10
0%
M
aj
or
am
pu
ta
ti
on
N
A,
m
or
ta
lit
y
2%
24
m
on
th
s
(m
ea
n)
Le
g
sa
lv
ag
e
80
%
an
d
pa
te
nc
y
76
%
at
1
yr
,
m
or
ta
lit
y
51
%
du
ri
ng
fu
84
/N
A/
68
yr
s
CA
D
48
%,
ES
RD
42
%
In
fr
ap
op
lit
ea
l
PT
A
(m
os
tl
y
st
en
os
es
)
10
0%
M
aj
or
am
pu
ta
ti
on
N
A,
m
or
ta
lit
y
6%
24
m
on
th
s
(m
ea
n)
Le
g
sa
lv
ag
e
82
%
at
1
yr
,
m
or
ta
lit
y
35
%
du
ri
ng
fu
Sc
hn
ei
de
r,
20
01
10
1
11
0/
M
67
,
F4
3/
69
yr
s
CA
D
43
%,
ES
RD
69
%
Re
va
sc
ul
ar
is
at
io
n
us
in
g
ei
th
er
fe
m
-d
is
ta
l
by
pa
ss
,
co
m
bi
ne
d
SF
A
PT
A
an
d
di
st
al
by
pa
ss
gr
af
ti
ng
or
sh
or
t
di
st
al
by
pa
ss
gr
af
t
10
0%
N
A
23
m
on
th
s
(m
ea
n)
Le
g
sa
lv
ag
e
89
%,
pa
te
nc
y
78
%
at
2
yr
s,
m
or
ta
lit
y
N
A
Fa
gl
ia
,
20
02
10
2
21
9/
N
A/
N
A
CA
D
55
%,
ES
RD
4%
Fe
m
or
od
is
ta
l
an
d
in
fr
ap
op
lit
ea
l
PT
A
(o
f
st
en
os
es
>5
0%
)
94
%
M
aj
or
am
pu
ta
ti
on
5%
,
m
or
ta
lit
y
0%
12
m
on
th
s
(m
ed
ia
n)
,
ra
ng
e
5–
–3
0
Le
g
sa
lv
ag
e
N
A,
m
or
ta
lit
y
5.
3%
at
1
yr
D
or
w
ei
le
r,
20
02
10
3
46
/M
36
,
F1
0/
69
yr
s
CA
D
46
%,
ES
RD
13
%
Pe
da
l
by
pa
ss
gr
af
ts
10
0%
M
aj
or
am
pu
ta
ti
on
7%
,
m
or
ta
lit
y
2%
28
m
on
th
s
(m
ed
ia
n)
,
ra
ng
e
1–
–7
0
Le
g
sa
lv
ag
e
87
%
at
2
yr
s
Ba
rg
el
lin
i,
20
08
10
4
60
/M
41
,
F1
9/
69
.4
yr
s
CA
D
42
%,
CV
D
25
%
M
ul
ti
-l
ev
el
su
bi
nt
im
al
PT
A
in
pa
ti
en
ts
un
ﬁt
fo
r
su
rg
er
y
43
%
M
aj
or
am
pu
ta
ti
on
5%
,
m
or
ta
lit
y
5%
23
m
on
th
s
(m
ea
n)
,
ra
ng
e
0–
–4
8
Le
g
sa
lv
ag
e
93
.3
%,
m
or
ta
lit
y
10
%
at
1y
r
Fe
rr
ar
es
i,
20
09
10
5
10
1/
M
85
,
F1
6/
66
yr
s
CA
D
28
%,
ES
RD
3%
In
fr
ap
op
lit
ea
l
PT
A
10
0%
N
A
35
m
on
th
s
(m
ea
n)
Le
g
sa
lv
ag
e
93
%,
m
or
ta
lit
y
9%
du
ri
ng
fu
Chapter V: Diabetic Foot S69
As to hyperbaric oxygen therapy, a recent double-
blind RCT demonstrated a signiﬁcantly improved outcome
in the intervention group as the treated patients were
more likely to heal within 12 months: 25/48 (52%) vs.
12/42 (27%); p = 0.03.117 Notably, a favourable outcome
seems to be connected to moderate rather than severe
ischaemia.117––119 A recent systematic review by the NICE
Guidelines Development Group in the UK concluded that
the available data were insufﬁcient to demonstrate that the
intervention was cost-effective.120
Recommendation
Hyperbaric oxygen therapy may be indicated for a selected
group of diabetic ulcers, but it is not clear which patients
are likely to beneﬁt and what is the optimal duration.
(Level 1b; Grade A)
Negative-pressure wound therapy (NPWT) is used to
accelerate healing and to ease local wound therapy. The
prerequisite for optimal effect is that there is sufﬁcient
blood supply for ulcer healing. Armstrong et al. used a
TcPO2 50mmHg or toe pressure 30mmHg as inclusion
criteria in their large multicentre trial.58 NPWT does not
replace surgical wound debridement and measures to
improve blood circulation. There must be no signiﬁcant
infection or gangrene in the wound when NPWT is initiated.
Recommendation
Negative-pressure wound therapy appears to be as ef-
fective and, under certain circumstances, more effective
than other available local wound treatments in patients
without signiﬁcant infection.121,122 (Level 1a; Grade A)
5.11. Foot surgery and correction of deformities
There are surgical techniques to ofﬂoad non-infected ulcers,
including surgical excision, arthroplasties, metatarsal head
resections and Achilles tendon lengthening. These proce-
dures seem to expedite healing and reduce ulcer recurrence
after revascularisation or if tissue perfusion is adequate.123
Elective surgery should be considered to correct structural
deformities that cannot be accommodated by therapeutic
footwear.
Recommendation
Foot surgery to ofﬂoad pressure areas may be beneﬁcial to
prevent ulcer recurrence after revascularisation for neuro-
ischaemic diabetic foot ulcers. (Level 4; Grade 5)
5.12. Minor amputation and removal of necrotic tissue
Minor amputations can be performed under ankle blockade.
Minor amputations should be left open whenever skin
viability is compromised. Patients with restricted acral
gangrene or dry lesions usually beneﬁt from revascularisation
ﬁrst. Patients frequently need several debridements and
care lasting several months before ulcers have healed
even after successful bypass.111 Heel ulcers are especially
vulnerable as poor perfusion in the heel fat pad and the
danger of debriding into the calcaneus may expose the area
to deep infection. Once the ulcer bed infection has subsided,
healing per second intention, or covering of the wound
should be discussed.
Recommendation
Toe, ray and transmetatarsal amputations are preferred
whenever possible as they enable a broader distribution
of weight during ambulation.10 (Level 4; Grade 5)
5.13. Amputations
Amputations are urgent or curative.124 Indications for an
amputation include the removal of infected or gangrenous
tissue, controlling infection and creating a functional foot or
stump that can accommodate footwear or a prosthesis. The
preservation of leg length aids ambulation and decreases
energy expenditure. Yet the surgical site should heal
primarily. A closed toe and metatarsal amputation typically
leave the patient with a functional foot for walking.10,125––127
If the healing of a toe is in doubt, metatarsal amputations
should be used liberally after revascularisation. Piecemeal
amputations should be avoided. In situations involving
extensive tissue loss and precluding a functional foot, as
well as when there are non-healing wounds despite patent
revascularisation and for controlling sepsis, amputation
below the knee is necessary.128
Recommendation
Bedridden patients, poor ambulation that is not worsened
by amputation, life expectancy less than 1 year, and a
non-revascularizable leg are indications for performing a
major amputation, even above the knee when necessary.
(Level 4; Grade D)
6. Outcomes
6.1. Ulcer healing
As an example of the recent positive trend in healing rates,
it has been observed that 50––60% of ulcers had healed at
20 weeks of observation and more than 75% had healed
at 1 year.11 Yet it is difﬁcult to obtain reliable data on
ulcer healing rates in diabetic populations. Furthermore,
the deﬁnition and observation time may cause problems
in the assessment of wound healing. Typically, heel ulcers
heal slowly. The completeness of revascularisation seems
important as shown by the predictive value of post-
procedural TcPO2 measurements by Faglia et al.59 Complete
tissue healing after infrainguinal bypass, including the
healing of ischaemic tissue lesions and surgical wounds,
was 26% at 6 months and 63% at 1 year, which was slower
than in non-diabetics.129 The median time to complete
tissue healing was 213 days in diabetics and 159 days in
non-diabetics.129 In a large study by Apelqvist et al.,
801 patients underwent angiography, and 297 were treated
medically, 314 by an endovascular technique, and 190 by
open surgical revascularisation. Revascularisations improved
ulcer healing, whereas the number of ulcers and severity of
PAD as well as congestive heart failure and renal function
impairment were associated with poor ulcer healing.130
Renal failure has been reported to independently predict
non-healing of neuroischaemic foot lesions (OR 3.04).6
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6.2. Leg salvage
Leg salvage is a composite endpoint and only an indirect
measure of successful revascularisation –– only half of the
diabetic patients with CLI were observed to undergo major
amputation within 6 months if they were not candidates for
revascularisation.131 Occlusion of all three crural arteries,
dialysis, wound infection, multiple ulcers, oedema and
non-compliance to treatment increase the risk of major
amputation.16,51 Leg salvage rates of approximately 80% at
1 year and roughly 70% at 3 years have been reported after
revascularisations.97 Diabetic patients with end-stage renal
disease (ESRD) and gangrene are at high risk of losing their
leg despite successful infrapopliteal revascularisation.132,133
Proper patency data on revascularisations for ulcerated
diabetic feet are not available as almost all series mix
diabetics and non-diabetics as well as different indications
and levels of disease.97
6.3. Mortality
Diabetic patients with CLI have been observed to
have 53% mortality at 6 months if not suitable for
revascularisation.131 ESRD and coronary heart disease
increase mortality.51,130 Peri-operative mortality in reported
revascularisation series tends to be mostly below 5%.97
Mortality is roughly 10––20% at 1 year and 40––50% at
5 years after open surgery; long-term data are missing in
endovascular series.98
6.4. Quality of life
Successful revascularisation for critical ischaemia improves
the quality of life for diabetics.134,135 Concurrent diseases
limit the chances of improving quality of life. Indeed,
diabetics with impaired ambulatory status and gangrene
at presentation had an 83% probability (OR 10.5) of not
beneﬁting from the intervention, and for those also with
end-stage renal disease and prior vascular surgery, the
probability of failure was 93% (OR 23.7).136
Recommendation
Comorbidities, especially renal failure and impaired
ambulatory status, at presentation are major factors for
poor outcome in diabetics with ischaemic ulcers. These
comorbidities should be taken into consideration when
deciding whether or not to revascularise. (Level 2a;
Grade B)
7. Multidisciplinary team approach
7.1. Multidisciplinary team
Diabetic foot ulcers should be managed by a multidisci-
plinary team, comprising individuals who can deliver all the
necessary and wide-ranging skills: medical and surgical as
well as podiatric, nursing and orthotic experts.123 Using a
protocol-driven and multidisciplinary approach will lower
the number of diabetics suffering from numerous foot
complications. Education, presented in a structured and
organised manner, also plays an important role in the
prevention of foot problems when combined with podiatry
and the use of adequate preventive footwear and ofﬂoading
techniques.
The associated systemic factors that impair wound
healing need to be treated; these include hyperglycaemia,
cardiovascular disease, peripheral vascular disease, in-
creased incidence of bacterial infections, and plantar
pressure redistribution.137 The medical management of
ulcers includes ofﬂoading, treatment of infection (local,
cellulitis, osteomyelitis or sepsis), debridement, wound bed
preparation and dressings. Surgery is often needed to
revascularise the limb, to treat the infected ulcers and to
achieve ofﬂoading.
A multidisciplinary approach is supported by the complex-
ity of the disease in patients with diabetic foot ulcers as
most of them present with multi-organ disease. Comparative
cohort studies with regard to healing and amputations,
epidemiological studies on incidence and diabetic-foot-
related amputations as well as health economic studies
strongly support this approach.
Vascular diagnostics and intervention are an integral part
of the strategy but are implemented conservatively, the
main reason being a poorly functioning treatment chain
with delayed referrals to vascular centres.2,17 To improve
amputation prevention, this window of opportunity should
not be missed.4,6,16,29,30 According to the most optimistic
view, up to 85% of amputations may be prevented by a
multidisciplinary approach.17
Recommendation
Early referral and intervention are crucial for to improve
diabetic foot ulcer healing and to prevent amputation:
• Do non-invasive vascular testing to all individuals with
diabetes and a foot ulcer.
• Image if non-invasive tests indicate ischaemia or
when mild or questionable ischaemia is diagnosed and
conservative treatment (Table 1) does not promote
ulcer healing (in 4––8 weeks)
• Revascularise to repair distal perfusion to promote ulcer
healing whenever feasible.
(Level 2b; Grade B)
8. Summary
The incidence of diabetes is increasing, and diabetic foot
ulcers continue to be a growing challenge for healthcare as
well as for vascular services. A neuroischaemic diabetic foot
is far more common than is usually thought. From a practical
point of view, diabetics with neuroischaemic feet and the
small group of diabetics with purely ischaemic ulcerated
diabetic feet should be lumped together. A diabetic
foot ulcer should always be considered to have vascular
impairment unless otherwise proven.
There is a paucity of data on how to diagnose and treat
these diabetic patients in the best possible way. Most of the
studies dealing with neuroischaemic diabetic feet are not
comparable in terms of patient populations, interventions
or outcome. Therefore, there is an urgent need for a
paradigm shift in diabetic foot care –– i.e. a new approach
and classiﬁcation of diabetics with impaired perfusion with
regard to clinical practice and research. A multidisciplinary
approach needs to be implemented systematically so as to
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intervene with a diabetic foot with impaired arterial supply
to improve healing and to avoid amputation irrespective of
the technique chosen.
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